Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.

Cancer research and treatment - 1 Jul 2020

Han Mi-Ryung, Lee Sug Hyung, Park Jung Yoon, Hong Hyosun, Ho Jung Yoon, Hur Soo Young, Choi Youn Jin

Abstract excerpt

PURPOSE: The purpose of this study was to identify the clinical utility of circulating tumor DNA (ctDNA) from ascites and serial plasma samples from epithelial ovarian cancer (EOC) patients. MATERIALS AND METHODS: Using targeted next-generation sequencing, we analyzed a total of 55 EOC samples including ctDNA from ascites and serial plasma and gDNA from tumor tissues. Tumor tissues and ascites were collected...

Topics

Join the communities discussing this publication.

Adenocarcinoma, Clear Cell
Ascites
Circulating Tumor DNA
Cystadenocarcinoma, Serous
Longitudinal Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 32106643
DOI: 10.4143/crt.2019.700
PMCID: PMC7373868

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.PMID 32106643Read ↗

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.Semantic proximity Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.Semantic proximity Read ↗

Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.Semantic proximity Read ↗

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Semantic proximity Read ↗

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.Semantic proximity Read ↗

Advances in application of circulating tumor DNA in ovarian cancer.Semantic proximity Read ↗

Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian CancerSemantic proximity Read ↗

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.Semantic proximity Read ↗

Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas.Semantic proximity Read ↗

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceSemantic proximity Read ↗

Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.